A Drug-Drug Interaction Study Between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Last updated: May 7, 2025
Sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Overall Status: Completed

Phase

1

Condition

Healthy Volunteers

Treatment

Rosuvastatin

XW003 injection

Warfarin

Clinical Study ID

NCT06335134
SCW0502-1016
  • Ages 18-45
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This is a study of a drug-drug interaction between XW003 and Metformin, Warfarin, Rosuvastatin or Digoxin

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Male or female, 18-45 years old, inclusive;

  2. BMI: 20.0 to 30.0 kg/m2 , body weight: ≥50.0kg.

  3. Ability and willingness to participate in the study, give written informed consent,and comply with the study requirements and all protocol procedures.

Exclusion

Exclusion Criteria:

  1. Presence of clinically significant conditions (including but not limited torespiratory system, cardiovascular system, gastrointestinal system, endocrinesystem, immune system, integumentary system, nervous system, ENT or other relateddiseases);

  2. History of allergic diseases including asthma, urticaria or eczema, or history ofsensitivity to GLP-1 products, digoxin, warfarin, rosuvastatin or metformin;

  3. Known difficulty in swallowing tablets or history of gastrointestinal diseasesaffecting drug absorption;

  4. History of receiving any procedures that might affect drug absorption, distribution,metabolism or excretion;

  5. History of acute or chronic pancreatitis;

  6. History of documented or suspected hypoglycemic episodes within 6 months prior toscreening;

Study Design

Total Participants: 57
Treatment Group(s): 5
Primary Treatment: Rosuvastatin
Phase: 1
Study Start date:
July 14, 2023
Estimated Completion Date:
June 28, 2024

Study Description

This is a single-center, open-label, fixed-sequence study designed to assess the effect of once-weekly subcutaneous injections of XW003 on the pharmacokinetics of metformin, warfarin, rosuvastatin or digoxin. Approximately 56 healthy subjects are to be enrolled into 2 parallel trial groups, with 28 subjects and 2 drugs evaluated in each of the trial group

Connect with a study center

  • West China Second University Hospital, Sichuan University

    Chengdu, Sichuan
    China

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.